Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors
Status:
Recruiting
Trial end date:
2030-09-05
Target enrollment:
Participant gender:
Summary
This study will evaluate the combination of a poly (adenosine diphosphate-ribose) polymerase
(PARP) inhibitor, niraparib, with the programmed cell death protein 1 (PD-1) inhibitor,
dostarlimab in the pediatric population. This study will be conducted to determine the
recommended Phase 2 dose (RP2D) and evaluate the pharmacokinetics (PK), safety, and efficacy
of niraparib in combination with dostarlimab in pediatric participants with recurrent or
refractory solid tumors.